{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:34:36Z","timestamp":1790386476739,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.leukres.2021.106749","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T10:49:49Z","timestamp":1636627789000},"page":"106749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-8469","authenticated-orcid":false,"given":"Jane L.","family":"Liesveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7975-8919","authenticated-orcid":false,"given":"Andrea","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Azadniv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-0699","authenticated-orcid":false,"given":"Haley","family":"Misch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Nedrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-0418","authenticated-orcid":false,"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Mendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106749_bib0005","article-title":"Evolving treatment patterns and outcomes in older patients (\u226560 years) with AML: changing everything to change nothing?","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2021.106749_bib0010","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2021.106749_bib0015","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"R\u00e9cher","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2021.106749_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092934","article-title":"Targeting PI3K\/Akt\/mTOR in AML: Rationale and Clinical Evidence","volume":"9","author":"Darici","year":"2020","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.leukres.2021.106749_bib0025","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14728220903136775","article-title":"Targeting the PI3K\/AKT\/mTOR signaling network in acute myelogenous leukemia","volume":"18","author":"Martelli","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7092","key":"10.1016\/j.leukres.2021.106749_bib0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.leukres.2021.106749_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.leukres.2021.106749_bib0040","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2008.243","article-title":"Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells","volume":"22","author":"Nishioka","year":"2008","journal-title":"Leukemia"},{"issue":"163","key":"10.1016\/j.leukres.2021.106749_bib0045","article-title":"Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma","volume":"8","author":"Chakraborty","year":"2008","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2021.106749_bib0050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.leukres.2009.01.041","article-title":"Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia","volume":"33","author":"Xu","year":"2009","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.leukres.2021.106749_bib0055","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.leukres.2013.09.002","article-title":"A phase I study of decitabine and rapamycin in relapsed\/refractory AML","volume":"37","author":"Liesveld","year":"2013","journal-title":"Leuk. Res."},{"issue":"25","key":"10.1016\/j.leukres.2021.106749_bib0060","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2021.106749_bib0065","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2021.106749_bib0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2021.106749_bib0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2021.106749_bib0080","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106749_bib0085","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2352-3026(18)30213-8","article-title":"10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck","volume":"6","author":"Cashen","year":"2019","journal-title":"Lancet Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2021.106749_bib0090","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2021.106749_bib0095","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","article-title":"Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia","volume":"103","author":"Roboz","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106749_bib0100","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","author":"DiNardo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106749_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106749_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020224","article-title":"Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia","volume":"11","author":"Ferrara","year":"2019","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.leukres.2021.106749_bib0115","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1080\/10428194.2020.1761964","article-title":"Venetoclax is safe and efficacious in relapsed\/refractory AML","volume":"61","author":"Ganzel","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2021.106749_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2021.106749_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1289524","article-title":"Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia","volume":"58","author":"Khan","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2021.106749_bib0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","article-title":"Dueling for dual inhibition: Means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML","volume":"32","author":"Herschbein","year":"2018","journal-title":"Blood Rev."},{"issue":"13","key":"10.1016\/j.leukres.2021.106749_bib0135","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","article-title":"Dual mTORC2\/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors","volume":"17","author":"Altman","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2021.106749_bib0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020102118","article-title":"Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition","volume":"118","author":"Fan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.leukres.2021.106749_bib0145","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell. Mol. Life Sci.: CMLS"},{"issue":"12","key":"10.1016\/j.leukres.2021.106749_bib0150","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2015.130351","article-title":"Co-administration of the mTORC1\/TORC2 inhibitor INK128 and the Bcl-2\/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation","volume":"100","author":"Rahmani","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106749_bib0155","article-title":"The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia","author":"Li","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.leukres.2021.106749_bib0160","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1152\/physiolgenomics.00173.2013","article-title":"Rational combination of dual PI3K\/mTOR blockade and Bcl-2\/-xL inhibition in AML","volume":"46","author":"Vachhani","year":"2014","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.leukres.2021.106749_bib0165","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies","author":"Zucenka","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2021.106749_bib0170","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106749_bib0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2017.11.022","article-title":"Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo","volume":"148","author":"Su","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106749_bib0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621017501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:49Z","timestamp":1758934909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621017501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"alternative-id":["S0145212621017501"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106749","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106749"}}